Slingshot members are tracking this event:

PDUFA Date of April 2017 for Pfizer's (PFE) Supplemental New Drug Application (sNDA) for Ibrance/Letrozole in Postmenopausal Women with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Supplemental New Drug Application, Snda, Ibrance, Letrozole, Postmenopausal Women, Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2, Metastatic Breast Cancer, Er+, Her2-